A Double-blind, Randomized, Placebo-controlled, Parallel Group, Multicenter, Dose-ranging Study to Assess the Efficacy and Safety of Ciclesonide HFA Nasal Aerosol in Adult and Adolescent Patients 12 Years and Older With Seasonal Allergic Rhinitis (SAR).

Trial Profile

A Double-blind, Randomized, Placebo-controlled, Parallel Group, Multicenter, Dose-ranging Study to Assess the Efficacy and Safety of Ciclesonide HFA Nasal Aerosol in Adult and Adolescent Patients 12 Years and Older With Seasonal Allergic Rhinitis (SAR).

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Dec 2016

At a glance

  • Drugs Ciclesonide (Primary)
  • Indications Seasonal allergic rhinitis
  • Focus Therapeutic Use
  • Sponsors ALTANA Pharma
  • Most Recent Events

    • 04 May 2012 Company added in association field as reported by ClinicalTrials.gov.
    • 25 Sep 2009 Integrated trial information from CTP 31721 (written from MR 9086463) with this record, since it was a duplicate.
    • 01 Aug 2009 Efficacy and tolerability results reported in the Annals of Allergy, Asthma & Immunology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top